Pre-Stenting Inflammatory Burden Index (IBI) as a Predictor of Survival and Postoperative Complications in Patients with Obstructive Colorectal Cancer

支架置入术前炎症负荷指数(IBI)作为梗阻性结直肠癌患者生存率和术后并发症的预测指标

阅读:3

Abstract

OBJECTIVES: Growing evidence suggests that cancer prognosis is influenced by the host's immune-inflammatory environment. The inflammatory burden index (IBI) is a newly established, potent inflammation-based marker easily calculated from laboratory findings. We evaluated the prognostic significance of IBI in patients with nonmetastatic obstructive colorectal cancer (OCRC) who underwent curative surgery following insertion of a self-expandable metallic stent as a bridge to curative surgery. METHODS: Eighty-six patients with pathological stages I-III OCRC were retrospectively analyzed to investigate the association between IBI and short- and long-term results. RESULTS: This study included 50 males and 36 females. The median age was 71.5 years, and the median follow-up time was 43 months. There were 34 postoperative complications, including 17 infectious complications. Sixty-three patients were classified as pre-stenting IBI-high using a cutoff of 0.9. Multivariate analyses revealed that high IBI was independently correlated with poorer disease-free survival (DFS) [hazard ratio (HR) = 4.10, 95% confidence interval (CI) 1.37-12.28, P = 0.012] and overall survival (OS) (HR = 9.32, 95% CI 1.15-75.63, P = 0.037). Moreover, patients with a high IBI had significantly more postoperative (P = 0.013) and infectious complications (P = 0.034). The preoperative IBI values had no prognostic significance. CONCLUSIONS: A high pre-stenting IBI was independently associated with poor DFS and OS. Additionally, it serves as a robust predictor of postoperative and infectious complications. Given that IBI can be easily derived from routine laboratory tests, its clinical utility is readily applicable in daily practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。